1. Home
  2. TENX vs CTM Comparison

TENX vs CTM Comparison

Compare TENX & CTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

N/A

Current Price

$1.48

Market Cap

73.8M

Sector

Health Care

ML Signal

N/A

CTM

Castellum Inc.

HOLD

Current Price

$0.42

Market Cap

63.1M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
TENX
CTM
Founded
1967
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
73.8M
63.1M
IPO Year
2001
2022

Fundamental Metrics

Financial Performance
Metric
TENX
CTM
Price
$1.48
$0.42
Analyst Decision
Buy
Analyst Count
10
0
Target Price
★ $10.29
N/A
AVG Volume (30 Days)
★ 1.4M
545.3K
Earning Date
11-05-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 83.33
EPS
N/A
★ N/A
Revenue
N/A
★ $52,866,001.00
Revenue This Year
N/A
$4.94
Revenue Next Year
N/A
$8.17
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 18.10
52 Week Low
$1.31
$0.34
52 Week High
$19.40
$1.24

Technical Indicators

Market Signals
Indicator
TENX
CTM
Relative Strength Index (RSI) 35.62 37.58
Support Level $1.34 $0.34
Resistance Level $2.01 $0.66
Average True Range (ATR) 0.12 0.04
MACD 0.00 -0.00
Stochastic Oscillator 6.25 41.41

Price Performance

Historical Comparison
TENX
CTM

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

About CTM Castellum Inc.

Castellum Inc is focused on building a successful technology services, solutions, and products company in the areas of cybersecurity, IT, electronic warfare, information warfare, system modernization, and information operations with businesses in the defense, federal, civilian, and commercial markets. Services include intelligence analysis, software development, software engineering, program management, strategic and mission planning, information assurance, cybersecurity and policy support, data analytics, and model-based systems engineering. The company maintains one operating and reportable segment, which is the delivery of products and services in the areas of information technology, electronic warfare, information warfare and cybersecurity in the governmental and commercial markets.

Share on Social Networks: